Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes

Author： Wysham Carol Lush Cameron Zhang Bei Maier Holly Wilhelm Ken

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.24, Iss.1, 2008-01, pp. : 79-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs

By Peyrot Mark Rubin Richard R. Polonsky William H. Jennie H.

Current Medical Research and Opinion, Vol. 26, Iss. 5, 2010-05 ,pp. : 1047-1054

Informa Healthcare

Access to resources Recommend Favorite

Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1158-1165

John Wiley & Sons Inc

Access to resources Recommend Favorite

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 9, 2015-09 ,pp. : 868-877

John Wiley & Sons Inc

Access to resources Recommend Favorite

Target intervention against multiple‐risk markers to reduce cardiovascular disease in patients with type 2 diabetes

By Gæde Peter Pedersen Oluf

Annals of Medicine, Vol. 36, Iss. 5, 2004-09 ,pp. : 355-366

Informa Healthcare

Access to resources Recommend Favorite

Early insulin therapy and the risk of cardiovascular disease in Type 2 diabetes

By Nicasio John McFarlane Samy I

Therapy, Vol. 2, Iss. 5, 2005-09 ,pp. : 685-688

Future Medicine

Access to resources Recommend Favorite